Clinical Features and Risk Factors of Relapse and Mortality in Thrombotic Thrombocytopenic Purpura Patients: A Seven-Year Experience

Background: Thrombotic thrombocytopenic purpura (TTP) is associated with microangiopathic hemolytic anemia, thrombocytopenia, and microvascular thrombosis. No comprehensive report exists on clinical characteristics and risk factors of relapse and mortality in Iranian TTP patients. In this study, we aimed to report clinical features of Iranian TTP patients, to evaluate disease relapse and mortality rate and their associated risk factors.

Materials and Methods: This study was a cohort study of patients diagnosed with microangiopathic hemolytic anemia admitted to the Shariati Hospital, Tehran, a referral center for TTP patients, from 2010 to 2017. Demographic, clinical, and laboratory data were recorded and patients were followed for 3 years regarding disease relapse and mortality.

Results: 114 patients (80 female, 34 male) with a mean age of 39.3 ± 14.99 years were included. Hematologic and neurologic symptoms were the most common manifestations. Abnormal laboratory findings at the presentation included thrombocytopenia, anemia, and elevated LDH. All patients were treated with plasma exchange, and 75.5% of them had a response to treatment, while the 3-year relapse and mortality rate was 23.6 and 26.3%. Lower platelet count was a predictor of disease relapse. Age, hematological, or neurological initial presentation were associated with TTP mortality.

Conclusion: Based on the largest study of TTP patients ever in Iran, the demographic and clinical characteristics of Iranian TTP patients are similar to other existing reports. Knowledge of the risk factors for TTP relapse and mortality could be useful to alert hematologists for prompt therapeutic actions when necessary.

1. Blombery P, Kivivali L, Pepperell D, et al. TTP registry steering committee. Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry. Intern Med J. 2016;46(1):71-9.
2. Sukumar S, Lammle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management. J Clin Med. 2021;10(3):536.
3. Hovinga JAK, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-11.
4. Joly BS, Stepanian A, Leblanc T, et al. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(11):e537-e546.
5. Joly BS, Coppo P, Veyradier A. Pediatric thrombotic thrombocytopenic purpura. Eur J Haematol. 2018;101(4):425-34.
6. Pavenski K, Huang SS, Patriquin CJ. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2021;14(11):1027-40.
7. Masias C, Cataland SR. Novel therapies in thrombotic thrombocytopenic purpura. Res Pract Thromb Haemost. 2017;2(1):19-26.
8. Pan T, Qi J, Tang Y, et al. N-Acetylcysteine as Prophylactic Therapy for Transplantation-Associated Thrombotic Microangiopathy: A Randomized, Placebo-Controlled Trial. Transplant Cell Ther. 2022;28(11):764 e1- e7.
9. Ssali FN, Aturinde J, Muyanja D, et al. Bortezomib As Frontline Therapy in the Management of TTP. Blood. 2021;138(Supplement 1):4226.
10. Jain N, Marquez C, Martell L. Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment. Blood. 2021;138(Supplement 1):4252.
11. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511-22.
12. Alwan F, Vendramin C, Vanhoorelbeke K, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood. 2017;130(4):466-71.
13. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-22.
14. Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematology Am Soc Hematol Educ Program. 2018; 2018(1):530-8.
15. Swart L, Schapkaitz E, Mahlangu JN. Thrombotic thrombocytopenic purpura: A 5-year tertiary care centre experience. J Clin Apher.2019;34(1):44-50.
16. Iqbal S, Zaidi SZ, Motabi IH, et al. Thrombotic thrombocytopenic purpura-analysis of clinical features, laboratory characteristics and therapeutic outcome of 24 patients treated at a Tertiary Care Center in Saudi Arabia. Pak J Med Sci. 2016;32(6):1494-1499.
17. El-Husseiny NM, Goubran H, Fahmy HM, et al. Outcome and relapse risks of thrombotic thrombocytopaenic purpura: an Egyptian experience. Postgrad Med J. 2012; 88(1042):433-6.
18. Wang Y, Zhang JY, Niu ZY, et al. [Clinical analysis of 14 patients with thrombotic thrombocytopenic purpura]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014; 22(2):407-11.
19. Sun L, Yu Z, Bu Y, et al. [The clinical studies of 51 patients with thrombotic thrombocytopenic purpura]. Zhonghua Xue Ye Xue Za Zhi. 2014;35(2):147-51.
20. Chaturvedi S, Carcioppolo D, Zhang L, et al. Management and outcomes for patients with TTP: analysis of 100 cases at a single institution. Am J Hematol. 2013;88(7):560-5.
21. Bae SH, Kim SH, Bang SM. Recent advances in the management of immune-mediated thrombotic thrombocytopenic purpura. Blood Res. 2022;57(S1):37-43.
22. George JN. Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol. 2012;87 Suppl 1:S88-91.
23. Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526-31.
24. Page EE, Kremer Hovinga JA, Terrell DR, et al. Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2016;127(24):3092-4.
25. Benhamou Y, Assie C, Boelle PY, et al. Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica. 2012;97(8):1181-6.
26. Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost. 2009;7(4):529-36.
27. Staley EM, Cao W, Pham HP, et al. Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura. Haematologica. 2019;104(1):166-75.
28. Frawley N, Ng A, Nicholls K, et al. Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single‐centre experience. Intern Med J. 2009;39(1):19-24.

Files	XML PDF (1MB)
Issue	Vol 17, No 3 (2023)
Section	Original Article(s)
DOI	https://doi.org/10.18502/ijhoscr.v17i3.13305
Keywords
Thrombotic thrombocytopenic purpura; Recurrence; Mortality; Risk factors

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Tavakoli Shiraji S, Kamranzadeh Foumani H, Mousavi SA, Vaezi M, Rad S, Babakhani D, Barkhordar M, Bahri T, Janbabaei G, Malekmohammadi A, Mohammadi S, Rostami MR, Mansouri V. Clinical Features and Risk Factors of Relapse and Mortality in Thrombotic Thrombocytopenic Purpura Patients: A Seven-Year Experience. Int J Hematol Oncol Stem Cell Res. 2023;17(3):156-166.

Vancouver

Download Citation